輝隆股份(002556.SZ):商務部最終認定原產於美國、歐盟及英國、日本的進口間甲酚存在傾銷
格隆匯 1 月 14日丨輝隆股份(002556.SZ)公佈,商務部於2021年1月14日發佈《關於原產於美國、歐盟及英國、日本的進口間甲酚反傾銷調查最終裁定的公吿》(2021年第2號)。商務部最終認定,原產於美國、歐盟及英國、日本的進口間甲酚存在傾銷,國內間甲酚產業受到實質損害,而且傾銷與實質損害之間存在因果關係。
根據《反傾銷條例》第三十八條規定,商務部向國務院關税税則委員會提出徵收反傾銷税的建議。國務院關税税則委員會根據商務部的建議作出決定,自2021年1月15日起,對原產於美國、歐盟及英國、日本的進口間甲酚徵收反傾銷税,實施期限自2021年1月15日起5年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.